Compare Amphastar Pharmaceuticals Inc (AMPH) vs BlackBerry Limited (BB) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

BlackBerry (BB) trades at $8.98, up 2.28% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats and a positive 2026 net income forecast of $60M signal a turnaround, though 2025 saw a net loss of $79M. The stock's valuation remains elevated with a P/E of 89.8 and P/S of 9.22. News highlights growth in QNX and secure communications, with the stock gaining 125% year-to-date as of August 2026, though it has pulled back 35% from its peak.

The outlook hinges on execution of growth in QNX and secure communications, with FY2027 guidance suggesting 11% revenue growth and 20% adjusted EBITDA margin expansion. Risks include premium valuation, cyclical industry exposure, and reliance on long-dated QNX royalties. Analyst consensus is cautious with 85.7% hold ratings, but a $10.50 price target implies potential upside if operational improvements materialize.